Nicotinamide riboside chloride: A potent neuroprotector and therapeutic candidate for alcohol-induced cognitive impairment
en-GBde-DEes-ESfr-FR

Nicotinamide riboside chloride: A potent neuroprotector and therapeutic candidate for alcohol-induced cognitive impairment

21/07/2026 Compuscript Ltd

Excessive alcohol consumption is a major contributor to cognitive impairment and neurodegenerative disorders, yet effective therapies that directly target alcohol-induced neuronal injury remain unavailable. Mounting evidence suggests that mitochondrial dysfunction plays a central role in alcohol-mediated brain damage, but the mechanisms responsible for mitochondrial failure are not fully understood.

A new study published in Genes & Diseases by researchers from Chongqing Medical University and The First Medical Centre of Chinese PLA General Hospital, demonstrates that nicotinamide riboside chloride (NRC), a precursor of nicotinamide adenine dinucleotide (NAD⁺), protects neurons from alcohol-induced injury by restoring mitochondrial quality control through coordinated activation of the mitochondrial unfolded protein response (UPRmt) and mitophagy.

By utilizing in vivo mouse models subjected to alcohol liquid feeding alongside in vitro HT-22 neuronal cells, the researchers systematically evaluated cognitive behaviors and underlying mitochondrial dynamics. The behavioral and molecular data conclusively revealed that excessive alcohol exposure significantly exacerbates cognitive impairments, evident through increased escape latency and a notably thinned hippocampal dentate gyrus (DG) zone.

Crucially, the study uncovered that alcohol forces destructive mitochondrial fragmentation, evidenced by an increased number of abnormally small, fragmented mitochondria and a severe accumulation of reactive oxygen species (ROS). Comprehensive proteomic analyses of HT-22 cells further deciphered the complex intracellular networks, revealing that this toxic pathology is deeply intertwined with massive apoptosis and suppressed cell viability.

To directly counter these severe neurodegenerative effects, the researchers explored the therapeutic potential of NRC supplementation. Remarkably, in vivo and in vitro evaluations confirmed that the administration of NRC successfully reversed the aggravated pathology, fundamentally mitigating alcohol-induced cognitive impairments and suppressing the widespread inflammatory and apoptotic responses, including sharp reductions in the expression of Bax and Caspase-9. At the cellular level, NRC treatment completely reversed the structural damage, forcefully promoting mitochondrial elongation, restoring a healthy rod-shaped morphology, and rescuing both ATP production and mitochondrial membrane potential. Extensive molecular assays deciphered the exact signaling cascade, proving that NRC exerts its powerful neuroprotection primarily by enhancing Fundc1-dependent mitophagy.

Furthermore, NRC strongly modulated the unfolded protein response (UPR) by upregulating essential mitochondrial stress-response genes, specifically Atf5 and Lonp1, to actively restore overall mitochondrial integrity. While these comprehensive data robustly highlight the critical influence of tightly regulated mitochondrial quality control in protecting neuronal networks from alcohol toxicity, additional clinical studies are necessary to translate these specific protective pathways into human applications.

In conclusion, elucidating the significant neuroprotective role of NRC offers a powerful new strategy to combat alcohol-induced brain damage. This substantial finding directly positions targeted metabolic modulation, specifically through nicotinamide riboside chloride intervention, as a highly compelling therapeutic candidate for the next generation of treatments targeting substance-induced cognitive decline and neurodegeneration.

Reference
Title of Original Paper: The therapeutic effect of nicotinamide riboside chloride on ameliorating alcohol-induced neuronal damage with a focus on mitochondrial unfolded protein response and mitophagy
Journal: Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.
DOI: https://doi.org/10.1016/j.gendis.2025.101886

Funding Information:
Chongqing Graduate Student Research Innovation Project (No. CYB23192, Chongqing, China)
Independent Innovation Scientific Project of Chinese PLA General Hospital (No. 22QNCZ058, Beijing, China)

# # # # # #

Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus Cite Score: 10.4 | Impact Factor: 14.6

# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)

# # # # # #
Attached files
  • (A) Experimental protocol. All animals were divided into 4 groups: negative control (NC) group, NRC group, alcohol group, and alcohol plus NRC group. Alcohol gradient feeding was conducted for 4 weeks. 2 weeks after alcohol gradient feeding, mice were treated with NRC (350 mg/kg•d) for 2 weeks. (B) The weight changes of mice under 4 weeks of control/alcohol liquid feeding. (C) Serum alcohol content. (D, E) Serum IL6 and MCP1 levels. (F–K) Behavior test. The mice were subjected to an open field test and Morris water maze test, described as total distance (F), average velocity (G), times in the central (H), escape latency (I), platform crossing (J), and time in the target quadrant (K). (L) Four weeks later, the mice were sacrificed, and the hippocampus was collected. Hematoxylin-eosin staining was used to observe the alcohol-derived brain damage. Data quantification was shown in Figure 1M. Each group included three mice, with three independent replicates performed. All data were presented as mean ± standard deviation. P-values were determined using a two-tailed unpaired t-test. ns, not significant; nd, non-detected; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001.
  • (A) ATP content of the mouse hippocampus. (B) Mitochondrial complex IV activity of the mouse hippocampus. (C, D) Transmission electron microscopy analysis of mitochondrial alterations in mouse brain tissue following alcohol exposure and NRC supplementation. (E, F) Significant improvement in mitochondrial permeability transition pore (MPTP) was observed after NRC treatment. (G, I) Mitochondrial membrane potential. (H, J) Mitochondrial ROS production. (K) ATP content of HT22 cells. (L) Mitochondrial complex IV activity of HT22 cells. (M, N) Mitochondrial integrity was used to detect changes in mitochondrial dynamics in the negative control (NC) group, NRC group, alcohol group, and the alcohol plus NRC group, and the average length of mitochondria in cells was measured (scale bar: 50 μm). The results were shown by the representative images and their corresponding quantitative results. Each group included three mice, with three independent replicates performed. Each value was expressed as mean ± standard deviation (n = 3 independent experiments). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001.
  • (A–C) Western blotting of mitophagy protein (Fundc1, Mito-LC3) expression treated with NRC. (D, E) The co-immunofluorescence of mitochondria and lysosomes indicated mitophagy. (F) Cell viability assays of HT22 cells treated with 5 μM MF094 (mitophagy inhibitor) for 6 h before alcohol exposure. (G–I) Effect of mitophagy inhibition on ATP content and mitochondrial permeability transition pore. Each value was expressed as mean ± standard deviation (n = 3 independent experiments). ns, no significant; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001.
21/07/2026 Compuscript Ltd
Regions: Europe, Ireland, Asia, China
Keywords: Science, Life Sciences

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by AlphaGalileo Terms Of Use Privacy Statement